The recent revision of US Pharmacopoeia (USP) Chapter <1724> brings clarity to the testing of semisolids – topical products for the relief of dermatological conditions – mirroring the framework already in place for transdermal drug products (TDPs). In this article we survey the regulatory framework for topical and transdermal drug delivery, focusing particularly on the in vitro tests specified for the performance testing for semisolids.
This article was taken from American Pharmaceutical Nov/Dec 2016.
